Pardes Biosciences Inc.

02/03/2022 | Press release | Distributed by Public on 02/03/2022 06:02

Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections